Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. LUMIBIRD
  6. News
  7. MarketScreener Strategies
    LBIRD   FR0000038242

LUMIBIRD

(LBIRD)
  Report
Real-time Quote. Real-time Euronext Paris - 06/25 05:08:01 am
16.8 EUR   +0.24%
06/11LUMIBIRD : The trend should regain control
04/28LUMIBIRD : General meeting streamed live on may 4, 2021
GL
04/27GLOBAL MARKETS LIVE : Tesla, UBS, Novartis...
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

LUMIBIRD : The trend should regain control

06/11/2021 | 03:29am EDT
long trade
Live
Entry price : 15.96€ | Target : 19.5€ | Stop-loss : 14.3€ | Potential : 22.18%
The current trading zone is interesting to the point that investors should pay attention to the stock and anticipate a return of the underlying upward trend.
Investors have an opportunity to buy the stock and target the € 19.5.
LUMIBIRD : LUMIBIRD : The trend should regain control
Summary
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.

Strengths
  • The company is in a robust financial situation considering its net cash and margin position.
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • The group usually releases upbeat results with huge surprise rates.

Weaknesses
Ratings chart
Subsector Other Advanced Medical Equipment & Technology
1st jan.Capitalization (M$)Investor Rating
LUMIBIRD19.37%444
THERMO FISHER SCIENTIFIC6.06%194 164
DANAHER CORPORATION20.35%191 622
INTUITIVE SURGICAL, INC.10.57%107 113
SHENZHEN MINDRAY BIO-MEDICA..8.43%86 774
ILLUMINA, INC.26.51%68 338
SIEMENS HEALTHINEERS AG21.25%68 248
EDWARDS LIFESCIENCES CORPOR..13.78%65 123
BOSTON SCIENTIFIC CORPORATI..21.59%62 222
KONINKLIJKE PHILIPS N.V.-3.78%46 100
AGILENT TECHNOLOGIES, INC.23.78%44 506
More Results

ę MarketScreener.com 2021

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials
Sales 2021 158 M 189 M 189 M
Net income 2021 15,3 M 18,2 M 18,2 M
Net cash 2021 0,35 M 0,42 M 0,42 M
P/E ratio 2021 24,8x
Yield 2021 -
Capitalization 372 M 444 M 444 M
EV / Sales 2021 2,35x
EV / Sales 2022 2,03x
Nbr of Employees 776
Free-Float 42,9%
Upcoming event on LUMIBIRD
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 3
Last Close Price 16,76 €
Average target price 17,35 €
Spread / Average Target 3,52%
EPS Revisions
Managers and Directors
Marc Paul Marcel Le Flohic Chairman & Chief Executive Officer
Pierre Vallalta Director-Finance & Administrative
Nomblot-Gourhand Aude Director-Finance & Secretary
Philippe MÚtivier Director-Marketing, Research & Development
Patrick Maine Chief Technical Officer